dr. J.A.N. (Jannick) Dorresteijn
Assistant Professor - medical
- Internal Medicine
Contact
Biography
Jannick Dorresteijn studied Medicine (2009) and Clinical Epidemiology (2011) at Utrecht University. His doctoral research focused on personalizing preventive treatment of cardiovascular disease based on statistical algorithms that support shared-decision making in the doctor’s office. He conducted this research partly at Harvard University. In 2013 this led to a promotion with honors (‘cum laude’) at Utrecht University. He trained as an Internist (2012-2019) at the Diakonessenhuis Utrecht and the University Medical Center Utrecht. In 2016 he received a Dekker grant from the Dutch Heart Foundation to continue his research. In 2018, this research resulted in the go-live of http://U-Prevent.com, a website that makes available statistical algorithms for personalization of preventive medication for cardiovascular diseases for use in clinical practice. From 2019-2020 he worked as an Internist-Specialist in Vascular Medicine at Rijnstate hospital in Arnhem and since 2020 at the University Medical Center Utrecht.
Research Output (47)
Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people
Jaspers Nicole E.M., Blaha Michael J., Matsushita Kunihiro, Van Der Schouw Yvonne T., Wareham Nicholas J., Khaw Kay Tee, Geisel Marie H., Lehmann Nils, Erbel Raimund, Jöckel Karl Heinz, Van Der Graaf Yolanda, Verschuren W. M.Monique, Boer Jolanda M.A., Nambi Vijay, Visseren Frank L.J., Dorresteijn Jannick A.N. 14 mrt 2020, In: European heart journal. 41 , p. 1190-1199 10 p.
Treatment of hypercholesterolaemia in older adults calls for a patient-centred approach
Kleipool Emma E.F., Dorresteijn Johannes A.N., Smulders Yvo M., Visseren Frank L.J., Peters Mike J.L., Muller Majon 28 nov 2019, In: Heart. 106 , p. 261-266 6 p.
Heterogeneity of treatment effects from an intensive lifestyle weight loss intervention on cardiovascular events in patients with type 2 diabetes:Data from the look AHEAD trial
De Vries Tamar I., Dorresteijn Jannick A.N., Van Der Graaf Yolanda, Visseren Frank L.J., Westerink Jan 1 okt 2019, In: Diabetes Care. 42 , p. 1988-1994 7 p.
Risk prediction tools in cardiovascular disease prevention:A report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP)
Rossello Xavier, Dorresteijn Jannick A.N., Janssen Arne, Lambrinou Ekaterini, Scherrenberg Martijn, Bonnefoy-Cudraz Eric, Cobain Mark, Piepoli Massimo F., Visseren Frank L.J., Dendale Paul okt 2019, In: European Journal of Cardiovascular Nursing. 18 , p. 534-544 11 p.
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease:results from the COMPASS trial
de Vries Tamar I., Eikelboom John W., Bosch Jackie, Westerink Jan, Dorresteijn Jannick A.N., Alings Marco, Dyal Leanne, Berkowitz Scott D., van der Graaf Yolanda, Fox Keith A.A., Visseren Frank L.J. 1 sep 2019, In: European Heart Journal. 40 , p. 3771-3778a
Risk prediction tools in cardiovascular disease prevention: A report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP)
Rossello Xavier, Dorresteijn Jannick A. N., Janssen Arne, Lambrinou Ekaterini, Scherrenberg Martijn, Bonnefoy-Cudraz Eric, Cobain Mark, Piepoli Massimo F., Visseren Frank L. J., Dendale Paul sep 2019, In: European Journal of Preventive Cardiology. 26 , p. 1534-1544 11 p.
Observational study of the medical management of patients with peripheral artery disease
Saratzis A., Jaspers N. E.M., Gwilym B., Thomas O., Tsui A., Lefroy R., Parks M., Htun V., Mera Z., Thatcher A., Bosanquet D., Forsythe R., Benson R., Dattani N., Dovell G., Lane T., Shalhoub J., Sidloff D., Visseren F. L.J., Dorresteijn J. A.N., Richards T., aug 2019, In: British Journal of Surgery. 106 , p. 1168-1177 10 p.
Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation:Results from the RE-LY Trial
Stam-Slob Manon C, Connolly Stuart J, van der Graaf Yolanda, van der Leeuw Joep, Dorresteijn Jannick A N, Eikelboom John W, Peters Ron J G, Alings Marco, Visseren Frank L J 18 jun 2019, In: Circulation. 139 , p. 2846-2856 11 p.
Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus
Berkelmans Gijs F N, Gudbjörnsdottir Soffia, Visseren Frank L J, Wild Sarah H, Franzen Stefan, Chalmers John, Davis Barry R, Poulter Neil R, Spijkerman Annemieke M, Woodward Mark, Pressel Sara L, Gupta Ajay K, van der Schouw Yvonne T, Svensson Ann-Marie, van der Graaf Yolanda, Read Stephanie H, Eliasson Bjorn, Dorresteijn Jannick A N 9 jan 2019, In: European Heart Journal. 40 , p. 2899-2906 8 p.
Cholesterolverlaging bij ouderen Starten, stoppen of doorgaan?
Kleipool Emma E.F., Dorresteijn Jannick A.N., Visseren Frank L.J., Hollander Monika, Peters Mike J.L., Muller Majon 1 jan 2019, In: Nederlands Tijdschrift voor Geneeskunde. 163